Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Eosinophilia is associated with worsening asthma severity and decreased lung function, with increased exacerbation frequency. We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor α that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): October 29 2016

Volume: 388

Issue: 10056

Affiliations

[1 ] Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: ebleec@wakehealth.edu.

[2 ] Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, BC, Canada.

[3 ] Département des Maladies Respiratoires, Aix Marseille University, APHM INSERM U1067 and CIC Nord, Marseille, France.

[4 ] Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

[5 ] Allergy and Asthma Specialists Medical Group, Huntington Beach, CA, USA.

[6 ] AstraZeneca, Gaithersburg, MD, USA.

[7 ] AstraZeneca, Cambridge, MA, USA.

[8 ] AstraZeneca, Gothenburg, Sweden.

Article

Publisher Item ID: S0140-6736(16)31324-1

DOI: 10.1016/S0140-6736(16)31324-1

PubMed ID: 27609408

SO-VID: 31d1b6b8-fe1e-4e6e-a7f4-19d6849b03c5

History

Data availability:

Comments

Comment on this article

scite_

Cited by 443

See all cited by